Alnylam Pharmaceuticals

RNAi therapeutics

ALNY · Nasdaq · United States

Share price · ALNY

$149.40-79.21 (-34.65%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.5M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALNY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 29 Oct 2026-25.1%
  2. 30 Jul 2026-28.3%
  3. 17 Jul 2026-5.5%
  4. 9 Jul 2026-3.3%
  5. 17 Apr 2026-3.3%
  6. 6 Apr 2026+3.6%
  7. 25 Mar 2026+6.7%

    Nothing announced by ALNY that day or the session before.

  8. 17 Feb 2026+5.8%
  9. 3 Feb 2026+3.7%
  10. 12 Jan 2026-6.9%

Share of unusual movement by asset

For each asset, the share of ALNY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Vutrisiran (AMVUTTRA)
events and moves
7shown from 8 days
Inclisiran (Leqvio)
events and moves
3shown from 8 days
Cemdisiran
events and moves
3shown from 8 days
Fitusiran (Qfitlia)
events and moves
2shown from 8 days
Zilebesiran
events and moves
1shown from 8 days
ALN-CIDEB
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—5%
Other company news (earnings, financing, releases naming no asset)—50%
Sessions with no dated event—45%

Assets

(15 total)
15Total Assets
6Approved
4Phase 3 / Filed
5Phase 1–2 / Early
13Diseases
Quick filter:
Showing 15 of 15 assets
Target & Modality
Fitusiran(Qfitlia)
Approved
Antithrombin (SERPINC1) mRNARNA / oligonucleotide
Hemophilia
Hemophilia A and B
Givosiran(GIVLAARI)
Approved
ALAS1 mRNA (RNAi)RNA / oligonucleotide
Acute Hepatic Porphyria
Inclisiran(Leqvio)
Approved
PCSK9RNA / oligonucleotide
Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia
Lumasiran(OXLUMO)
Approved
HAO1 (glycolate oxidase)RNA / oligonucleotide
Primary Hyperoxaluria
Primary Hyperoxaluria Type 1
Patisiran(ONPATTRO)
Approved
Transthyretin (TTR)RNA / oligonucleotide
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Polyneuropathy
Vutrisiran(AMVUTTRA)
Approved
Transthyretin (TTR)RNA / oligonucleotide
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy
Phase 3
CIDEBRNA / oligonucleotide
MASH / NASH
Phase 3
Complement C5RNA / oligonucleotide
Age-Related Macular DegenerationMyasthenia Gravis
Generalized Myasthenia Gravis
Phase 3
Transthyretin (TTR)RNA / oligonucleotide
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy
Phase 3
Angiotensinogen (AGT)RNA / oligonucleotide
Hypertension
Phase 2
PNPLA3RNA / oligonucleotide
MASH / NASH
Phase 2
APP mRNA (RNAi)RNA / oligonucleotide
Alzheimer's Disease
Phase 2
HSD17B13RNA / oligonucleotide
MASH / NASH
Phase 1
MAPT mRNA (RNAi/ASO)RNA / oligonucleotide
Alzheimer's Disease
Phase 1
Apolipoprotein C-III (APOC3)RNA / oligonucleotide
Atherosclerotic Cardiovascular DiseaseCardiovascular Disease / DyslipidemiaDyslipidemia
Hypertriglyceridemia

Upcoming events

(25 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (7)
January 2027 (1)
Inclisiran · LeqvioPhase 3Acute Coronary Syndrome
Est. primary completion 2027-01-16 · NCT07102628 · CT.gov ↗
What to watch
March 2027 (1)
Fitusiran · QfitliaPhase 3Hemophilia
Est. primary completion 2027-03-25 · NCT05662319 · CT.gov ↗
What to watch
May 2027 (1)
Inclisiran · LeqvioPhase 3Atherosclerotic Cardiovascular Disease
Est. primary completion 2027-05-10 · NCT05030428 · CT.gov ↗
What to watch
August 2027 (3)
MivelsiranPhase 2Cerebral Amyloid Angiopathy
Est. primary completion 2027-08-09 · NCT06393712 · CT.gov ↗
What to watch
ALN-PNPPhase 1/2Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Est. primary completion 2027-08-10 · NCT05648214 · CT.gov ↗
What to watch
ALN-CIDEBPhase 1/2Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Est. primary completion 2027-08-17 · NCT06836609 · CT.gov ↗
What to watch
December 2027 (1)
NucresiranPhase 3Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
Est. primary completion 2027-12-27 · NCT07223203 · CT.gov ↗
What to watch
2028 (7)
February 2028 (1)
Inclisiran · LeqvioPhase 3Atherosclerotic Cardiovascular Disease (ASCVD)
Est. primary completion 2028-02-03 · NCT06813911 · CT.gov ↗
What to watch
March 2028 (3)
Inclisiran · LeqvioPhase 3Familial Hypercholesterolemia - Homozygous
Est. primary completion 2028-03-21 · NCT06597006 · CT.gov ↗
What to watch
Inclisiran · LeqvioPhase 3Familial Hypercholesterolemia - Heterozygous
Est. primary completion 2028-03-21 · NCT06597019 · CT.gov ↗
What to watch
Vutrisiran · AMVUTTRAPhase 3Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Est. primary completion 2028-03-31 · NCT06679946 · CT.gov ↗
What to watch
April 2028 (1)
Rapirosiran (ALN-HSD)Phase 2Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Est. primary completion 2028-04-27 · NCT05519475 · CT.gov ↗
What to watch
July 2028 (1)
CemdisiranPhase 3Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Est. primary completion 2028-07-31 · NCT06541704 · CT.gov ↗
What to watch
October 2028 (1)
CemdisiranPhase 3Paroxysmal Nocturnal Hemoglobinuria
Est. primary completion 2028-10-10 · NCT05744921 · CT.gov ↗
What to watch
2029 (5)
January 2029 (1)
ALN-CIDEBPhase 2Metabolic Dysfunction-Associated Steatohepatitis, MASH
Est. primary completion 2029-01-29 · NCT07631637 · CT.gov ↗
What to watch
March 2029 (1)
ALN-CIDEBPhase 3Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Est. primary completion 2029-03-03 · NCT07854782 · CT.gov ↗
What to watch
April 2029 (1)
Inclisiran · LeqvioPhase 3Primary Prevention of Atherosclerotic Cardiovascular Disease
Est. primary completion 2029-04-16 · NCT05739383 · CT.gov ↗
What to watch
May 2029 (1)
ALN-CIDEBPhase 2Alcohol-Associated Liver Disease, ALD
Est. primary completion 2029-05-07 · NCT07933328 · CT.gov ↗
What to watch
August 2029 (1)
Fitusiran · QfitliaPhase 3Hemophilia
Est. primary completion 2029-08-04 · NCT07285460 · CT.gov ↗
What to watch
2030 (5)
January 2030 (1)
CemdisiranPhase 3Paroxysmal Nocturnal Hemoglobinuria
Est. primary completion 2030-01-18 · NCT07154745 · CT.gov ↗
What to watch
March 2030 (1)
ALN-PNPPhase 2Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Est. primary completion 2030-03-15 · NCT07527910 · CT.gov ↗
What to watch
May 2030 (2)
MivelsiranPhase 2Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Est. primary completion 2030-05-18 · NCT07636811 · CT.gov ↗
What to watch
NucresiranPhase 3Transthyretin Amyloidosis With Cardiomyopathy
Est. primary completion 2030-05-28 · NCT07052903 · CT.gov ↗
What to watch
September 2030 (1)
ZilebesiranPhase 3High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Est. primary completion 2030-09-23 · NCT07181109 · CT.gov ↗
What to watch
2032 (1)
March 2032 (1)
Inclisiran · LeqvioPhase 3Heterozygous or Homozygous Familial Hypercholesterolemia
Est. primary completion 2032-03-25 · NCT05682378 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

November 2026FDA action dateCemdisiranCemdisiran PDUFA target action date (generalized myasthenia gravis)
US, FDA · FDA · Source ↗

Recent

18 November 2026ApprovalCemdisiranFDA approves Livsayis (cemdisiran) for gMG
US, FDA · Source ↗
22 June 2026Filing acceptedCemdisiranFDA accepts cemdisiran NDA for generalized myasthenia gravis (priority review)
US, FDA · Regeneron Pharmaceuticals · Source ↗
22 June 2026Filing acceptedCemdisiranEMA accepts cemdisiran marketing authorisation application for generalized myasthenia gravis
EU, EMA · Regeneron Pharmaceuticals · Source ↗
30 August 2025Topline resultZilebesiranKARDIA-3 (zilebesiran add-on) did not meet its pre-specified significance definition
Roche; Alnylam · Source ↗
9 October 2023Complete response letterPatisiran (ONPATTRO)FDA issues complete response letter for the patisiran sNDA in ATTR cardiomyopathy
US, FDA · Alnylam Pharmaceuticals · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.5B$409M$1.8B+ $1.8B short-term inv.—$341M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.3B$413M$1.7B+ $1.6B short-term inv.—report ↗
2025-Q3$1.2B$359M$1.5B+ $1.2B short-term inv.—$325M operating cash flowreport ↗
2025-Q2$774M$324M$1.1B+ $1.7B short-term inv.$66M$154M operating cash flowreport ↗
2025-Q1$594M$265M$1.0B+ $1.6B short-term inv.$57M-$118M operating cash flowreport ↗
2024-Q3$501M$271M$1.1B+ $1.7B short-term inv.$112M$44M operating cash flowreport ↗
2024-Q2$660M$294M$971M+ $1.6B short-term inv.$17M$124M operating cash flowreport ↗
2024-Q1$494M$261M$685M+ $1.7B short-term inv.$66M-$82M operating cash flowreport ↗
2023-Q3$751M$253M$1.0B+ $1.4B short-term inv.—$359M operating cash flowreport ↗
2023-Q2$319M$249M$660M+ $1.4B short-term inv.$276M-$59M operating cash flowreport ↗
2023-Q1$319M$231M$674M+ $1.4B short-term inv.$174M-$166M operating cash flowreport ↗
2022-Q3$264M$245M$1.1B+ $1.2B short-term inv.$406M-$115M operating cash flowreport ↗
2022-Q2$225M$206M$578M+ $1.5B short-term inv.$277M-$123M operating cash flowreport ↗
2022-Q1$213M$170M$536M+ $1.7B short-term inv.$240M-$171M operating cash flowreport ↗
2021-Q3—$195M$1.1B+ $1.2B short-term inv.$205M-$134M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.7B$1.3B$1.7B+ $1.3B short-term inv.—$524M operating cash flowreport ↗

Alnylam reported full-year 2025 total revenues of $3,713.94M, up 65.2% YoY, with GAAP net income of $313.75M. R&D spend was $1,319.78M, up 17.2% YoY. Cash and equivalents were $1,658.81M, and cash, cash equivalents and marketable securities totaled $2.91B as of December 31, 2025.

For 2026, the company guided to total net product revenues of $4,900M-$5,300M, including TTR product revenues of $4,400M-$4,700M and Rare product revenues of $500M-$600M, with collaboration and royalty revenues of $400M-$500M and non-GAAP R&D and SG&A expenses of $2,700M-$2,800M. The company launched its Alnylam 2030 strategy and announced 2026 pipeline goals including four clinical readouts, three ongoing pivotal studies, three Phase 2 initiations, and three or more new IND filings. Recent progress included the initiation of Phase 2 ALN-4324 in type 2 diabetes, Phase 1 ALN-2232 in obesity, advancement of ALN-4285 and ALN-4915 into clinical development, and a planned $250M expansion of its Norton, Massachusetts manufacturing facility using the siRELIS platform.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$2.2B$1.1B$969M+ $1.7B short-term inv.$70M-$8.3M operating cash flowreport ↗
2023-FY$1.8B$1.0B$815M+ $1.6B short-term inv.$110M$104M operating cash flowreport ↗
2022-FY$1.0B$883M$869M+ $1.3B short-term inv.$283M-$541M operating cash flowreport ↗
2021-FY$844M$792M$822M+ $1.5B short-term inv.$213M-$642M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($543K), 248 sales ($26.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Greenstreet Yvonne · director, Chief Executive OfficerGift11,000——Form 4
2026-11-10Sigal Charles Elliott · directorOpen-market purchase1,600$152.25$244KForm 4
2026-11-10PYOTT DAVID E I · directorOption exercise3,780$71.99$272KForm 4
2026-11-10PYOTT DAVID E I · directorOption exercise (derivative)3,780——Form 4
2026-11-09SCHULMAN AMY W · directorOpen-market purchase1,910$156.82$300KForm 4
2026-10-02SUPRAN BRYAN · EVP, CLO and SecretaryOpen-market sale1,758$226.88$399KForm 4
2026-09-19Greenstreet Yvonne · director, Chief Executive OfficerAward / grant107——Form 4
2026-06-01Cravatt Benjamin · directorAward / grant (derivative)4,393——Form 4